Trigeminal Neuralgia

Neurology·MeSH: Trigeminal Neuralgia

Prevalence

5.0 / 100K

4 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Phase 1/Phase 2(2)

Drug	Company
rp-008	Relief Therapeutics Holding SA (RLFTF)
varenicline	Relief Therapeutics Holding SA (RLFTF)

Phase 4(2)

Drug	Company
OnabotulinumtoxinA 100 UNT [Botox]	Revance Therapeutics, Inc. (RVNC)
Sodium Chloride 0.9% for Injection, Preservative Free	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 4 drugs in development for Trigeminal Neuralgia across 2 companies.

There are 2 clinical trials targeting Trigeminal Neuralgia tracked by BioSniper.

The estimated prevalence of Trigeminal Neuralgia is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.